Published in Proc Natl Acad Sci U S A on April 11, 1995
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. ACS Nano (2008) 1.90
Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell (1999) 1.74
Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene (2007) 1.69
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol (2008) 1.65
Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell (2004) 1.63
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res (2010) 1.16
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Exp Cell Res (2008) 1.08
Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci (2010) 1.03
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer (1996) 0.97
Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett (2007) 0.97
A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol (2006) 0.95
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest (1995) 0.89
An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother (2011) 0.86
Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer (2013) 0.83
Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles. PLoS One (2012) 0.79
Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One (2010) 0.79
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. Br J Cancer (2007) 0.77
Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. Br J Cancer (1996) 0.76
A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence-Quencher Probe as a Tool for Functional Antibody Screening. J Biomol Screen (2015) 0.75
Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (1962) 64.93
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Growth factor receptor tyrosine kinases. Annu Rev Biochem (1988) 8.67
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell (1986) 7.06
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A (1987) 3.64
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol (1989) 3.62
Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway. Cell (1994) 3.44
Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science (1990) 2.92
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell (1985) 2.75
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell (1992) 2.62
Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell (1990) 2.58
Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res (1990) 2.56
Endocytosis of growth factor receptors. Bioessays (1993) 2.03
Neu and its ligands: from an oncogene to neural factors. Bioessays (1993) 2.00
ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem (1994) 1.88
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry (1990) 1.81
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
Characteristics of cell lines established from human gastric carcinoma. Cancer Res (1990) 1.49
Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res (1992) 1.45
Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene (1988) 1.30
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res (1992) 1.24
Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res (1991) 1.15
Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene (1989) 1.15
Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer (1991) 1.07
Primary amines do not prevent the endocytosis of epidermal growth factor into 3T3 fibroblasts. Biochim Biophys Acta (1981) 1.01
Surface distribution and internalization of erbB-2 proteins. Exp Cell Res (1992) 0.92
Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res (1988) 0.89
Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol (1993) 0.88
Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. Oncogene (1990) 0.88
A single amino acid substitution is sufficient to modify the mitogenic properties of the epidermal growth factor receptor to resemble that of gp185erbB-2. EMBO J (1992) 0.87
Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer. Cancer Lett (1994) 0.79
Helping out in Bhopal. Nature (1985) 0.78
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature (1986) 7.90
Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med (1965) 7.27
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell (1999) 6.79
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry (1987) 3.94
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry (1987) 3.20
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 3.12
The localization of antigen in relation to specific antibody-producing cells. I. Use of a synthetic polypeptide [(T,G)-A--L] labelled with iodine-125. Immunology (1966) 3.09
Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem (2000) 3.06
Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem (1983) 2.94
Expression of epidermal growth factor receptors in human brain tumors. Cancer Res (1984) 2.83
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell (1992) 2.62
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol (2000) 2.47
The avian beta-adrenergic receptor: primary structure and membrane topology. Proc Natl Acad Sci U S A (1986) 2.45
Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A--L in CBA and C57 mice. J Exp Med (1967) 2.41
Antigenicity of some new synthetic polypeptides and polypeptidyl gelatins. Biochem J (1964) 2.40
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 2.33
Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron (1997) 2.33
A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol (1991) 2.27
Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc Natl Acad Sci U S A (1966) 2.25
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Role of optical configuration in the immunogenicity and specificity of synthetic antigens derived from multichain polyproline. J Biol Chem (1968) 2.19
Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development (1991) 2.16
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett (2001) 2.15
Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem (1997) 2.14
The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem (1999) 2.13
Immunological studies with synthetic polypeptides. Adv Immunol (1966) 2.10
Regulation of cell proliferation by epidermal growth factor. CRC Crit Rev Biochem (1983) 2.09
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res (2000) 2.07
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
Modified stock-eye ocular prosthesis. J Prosthet Dent (1985) 2.03
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron (1995) 2.02
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Neu and its ligands: from an oncogene to neural factors. Bioessays (1993) 2.00
Developmental expression of c-kit, a proto-oncogene encoded by the W locus. Development (1990) 1.99
Antigenicity: some molecular aspects. Science (1969) 1.98
The basic biology of HER2. Ann Oncol (2001) 1.97
Epidermal growth factor induces electrically silent Na+ influx in human fibroblasts. J Biol Chem (1982) 1.96
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene (2001) 1.95
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. EMBO J (1992) 1.93
Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc Natl Acad Sci U S A (1981) 1.87
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem (1998) 1.81
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry (1990) 1.81
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene (2007) 1.79
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
The nature of the antigenic determinant in a genetic control of the antibody response. J Exp Med (1969) 1.74
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J (1993) 1.74
Rotational diffusion of epidermal growth factor complexed to cell surface receptors reflects rapid microaggregation and endocytosis of occupied receptors. Proc Natl Acad Sci U S A (1981) 1.72
Regulation of antibody response by cells expressing histamine receptors. J Exp Med (1972) 1.70
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc Natl Acad Sci U S A (1971) 1.67
Antigen design and immune response. Harvey Lect (1973) 1.67
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene (1997) 1.64
Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol (1995) 1.63
Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem (1998) 1.62
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A (2000) 1.61
Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies. J Biol Chem (1985) 1.61
Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J (1997) 1.58
The genetic control of antibody specificity. J Exp Med (1969) 1.58
Comparative genetics of nucleotide binding site-leucine rich repeat resistance gene homologues in the genomes of two dicotyledons: tomato and arabidopsis. Genetics (2000) 1.56
Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. J Biol Chem (2000) 1.54
Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A (2000) 1.52
Thymus-independence of slowly metabolized immunogens. Proc Natl Acad Sci U S A (1972) 1.52
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta (1998) 1.51
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell (1992) 1.50
Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem (2001) 1.50
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J (1998) 1.49
Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst (1988) 1.49
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene (1996) 1.48
Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A (1979) 1.48
Changing indications for enucleations in Hadassah University Hospital, 1960-1989. Ophthalmic Epidemiol (1995) 1.48
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res (1975) 1.48
Synthetic antigens composed exclusively of L- or D-amino acids. I. Effect of optical configuration on the immunogenicity of synthetic polypeptides in mice. Immunology (1967) 1.47
Receptors for histamine can be detected on the surface of selected leukocytes. Science (1972) 1.46
Preparation and characterization of poly-DL-alanyl rabbit gamma-globulin. J Biol Chem (1965) 1.44
An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem (1996) 1.43
A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J (1991) 1.39
Specific leukocyte receptors for small endogenous hormones. Detection by cell binding to insolubilized hormone preparations. J Clin Invest (1973) 1.39
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol (1998) 1.38
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem (1996) 1.38